Norway ALS patients face a heartbreaking dilemma as they are excluded from a trial for a new medicine called ILB. Kirsten Jacobsen, 63, and Kjartan Børdal Hovgaard, 52, both with ALS, have been told they cannot participate in the study run by Oslo University Hospital. They have also been denied access to the medicine outside the trial, even though they offered to pay for it themselves. Kirsten Jacobsen expressed her frustration, stating that for her, there is no risk in trying these medicines since she will die anyway. She called the system inhuman.
The Patients' Desperate Situation
Kirsten Jacobsen and Kjartan Bovdal Hovgaard represent approximately 400 ALS patients in Norway. The study led by Oslo University Hospital has space for only 116 participants. Both patients have applied for access to ILB through an approval exemption, known as godkjenningsfritak, but were rejected. Abdullah Mohammud, a neurologist at Oslo University Hospital, applied on behalf of Kirsten Jacobsen in October last year. In his application, he wrote that the purpose was to secure the patient access to a potentially symptom-relieving and life-extending treatment. He emphasized it could help slow disease progression and preserve function.
The ILB Medicine and International Collaboration
The new medicine, ILB, is the result of a collaboration between Gothenburg University Hospital in Sweden and Queen Elizabeth Hospital in Birmingham, England. It is described as a promising treatment for ALS, a progressive neurodegenerative disease with no cure. The study aims to test ILB's effectiveness in slowing the disease. Project leader Angelina Hatlø Maniaol, a neurologist at Oslo University Hospital, explained that the goal is to find a new treatment, a brake medicine that can extend life. She clarified that patients are not being cured, and the probability of that is very small. The best outcome would be to prove that ILB works and pave the way for more studies.
Strict Study Criteria Exclude Many
Angelina Hatlø Maniaol stated that a large proportion of ALS patients do not meet the criteria to participate in the study. Many are too far along in the disease progression. To participate, patients must have functions that can be measured. She expressed sadness for patients who are turned away, acknowledging that those who are not included are left with no treatment and a certain death. This has raised ethical concerns among families and advocates. Hektor Hovgaard, Kjartan's brother, questioned the ethics of the situation. He argued that those excluded should receive the medicine through an approval exemption or in a separate research arm. He asked if this is justifiable.
Ethical Dilemmas in Healthcare Access
The denial of access has sparked a debate about patient rights and healthcare ethics in Norway. Patients like Kirsten and Kjartan feel abandoned by the system. Kirsten Jacobsen reiterated that she has nothing to lose by trying the medicine. The study's limited capacity highlights the challenges in balancing research protocols with compassionate care. The project leader emphasized that the study is designed to gather measurable data to validate the treatment's efficacy. However, this leaves many patients without hope. The application for approval exemption was a last resort for these patients, but it was denied, citing regulatory and procedural barriers.
Expert Insights on Treatment Hopes
Angelina Hatlø Maniaol provided further context on the study's objectives. She said that the hope is to find a new treatment that can extend life, but curing ALS is unlikely. The study is a step towards potentially larger trials if ILB proves effective. She acknowledged the pain of excluding patients but stressed the need for rigorous scientific methods. The medicine ILB represents a breakthrough in international medical research, but its accessibility remains limited. The collaboration between Swedish and English hospitals shows the global effort to combat ALS, yet national regulations can hinder patient access.
The System's Response and Future Implications
The healthcare system's response has been to adhere to study protocols and regulatory frameworks. This has left patients and families feeling that the system is inflexible and inhumane. The case of Kirsten and Kjartan illustrates a broader issue in medical trials where eligibility criteria can exclude those most in need. As ALS progresses rapidly, time is of the essence for patients. The denial of access outside the trial raises questions about patient autonomy and the role of payment in healthcare. Norway's system typically emphasizes equal access, but this situation shows gaps in handling experimental treatments.